Research and Markets Commercial Insight Hepatitis B and C - Awaiting New Develo

[Guest guest]

(never forget the business side of the meds.... Alley)

Research and Markets: Commercial Insight: Hepatitis B and C - Awaiting New

Developments

Wednesday July 28, 10:00 am ET

News and Analysis of Upcoming Hepatitis B and C Antivirals

DUBLIN, Ireland--(BUSINESS WIRE)--July 28, 2004-- Research and Markets

(http://www.researchandmarkets.com) has announced the addition of Commercial

Insight: Hepatitis B and C - Awaiting New Developments to their offering.

Introduction

The launch of the pegylated interferons has had a dramatic effect on the market

for hepatitis treatments, with the improvements in side-effect profile and

efficacy leading to significant drug switching. Companies involved in this

sector need to reassess their competitive position and understand the new

dynamics of this sector.

Scope

In-depth profiles of all leading hepatitis B and hepatitis C products, including

recent event screens and key clinical trial data

Analysis of historical sales performance of all leading hepatitis products,

including quarterly seven major market sales from 1999 to 2003

Country specific forecasts for all leading products up to 2014 and in-depth

analysis of key events that will impact sales

Detailed analysis of life-cycle management and revenue protection strategies

available to key players

Highlights

The hepatitis market is expected to exhibit rapid growth to 2010, with a CAGR

greater than other infectious disease sectors (CAGR 2000-2010 = 9.0%). In the

short-term, Datamonitor expects continued uptake of existing products to drive

such growth, through geographical expansion and increased targeting of niche

populations.

The current lack of clinical differentiation between Pegasys and Peg-Intron

highlights the importance of effective life-cycle management strategies. During

the next 5 years, securing additional indications and geographical expansion

will prove more influential in determining hepatitis C market success than

efficacy and safety profiles.

The clear limitations of current hepatitis B (HBV) antiviral have led to

increased research assessing the potential of HBV combination therapy.

Datamonitor believes that the development of this concept will lead to increased

investment in antiviral R & D, alongside greater licensing and partnership

activity.

http://biz./bw/040728/285381_1.html

[Guest guest]

(never forget the business side of the meds.... Alley)

Research and Markets: Commercial Insight: Hepatitis B and C - Awaiting New

Developments

Wednesday July 28, 10:00 am ET

News and Analysis of Upcoming Hepatitis B and C Antivirals

DUBLIN, Ireland--(BUSINESS WIRE)--July 28, 2004-- Research and Markets

(http://www.researchandmarkets.com) has announced the addition of Commercial

Insight: Hepatitis B and C - Awaiting New Developments to their offering.

Introduction

The launch of the pegylated interferons has had a dramatic effect on the market

for hepatitis treatments, with the improvements in side-effect profile and

efficacy leading to significant drug switching. Companies involved in this

sector need to reassess their competitive position and understand the new

dynamics of this sector.

Scope

In-depth profiles of all leading hepatitis B and hepatitis C products, including

recent event screens and key clinical trial data

Analysis of historical sales performance of all leading hepatitis products,

including quarterly seven major market sales from 1999 to 2003

Country specific forecasts for all leading products up to 2014 and in-depth

analysis of key events that will impact sales

Detailed analysis of life-cycle management and revenue protection strategies

available to key players

Highlights

The hepatitis market is expected to exhibit rapid growth to 2010, with a CAGR

greater than other infectious disease sectors (CAGR 2000-2010 = 9.0%). In the

short-term, Datamonitor expects continued uptake of existing products to drive

such growth, through geographical expansion and increased targeting of niche

populations.

The current lack of clinical differentiation between Pegasys and Peg-Intron

highlights the importance of effective life-cycle management strategies. During

the next 5 years, securing additional indications and geographical expansion

will prove more influential in determining hepatitis C market success than

efficacy and safety profiles.

The clear limitations of current hepatitis B (HBV) antiviral have led to

increased research assessing the potential of HBV combination therapy.

Datamonitor believes that the development of this concept will lead to increased

investment in antiviral R & D, alongside greater licensing and partnership

activity.

http://biz./bw/040728/285381_1.html

[Guest guest]

(never forget the business side of the meds.... Alley)

Research and Markets: Commercial Insight: Hepatitis B and C - Awaiting New

Developments

Wednesday July 28, 10:00 am ET

News and Analysis of Upcoming Hepatitis B and C Antivirals

DUBLIN, Ireland--(BUSINESS WIRE)--July 28, 2004-- Research and Markets

(http://www.researchandmarkets.com) has announced the addition of Commercial

Insight: Hepatitis B and C - Awaiting New Developments to their offering.

Introduction

The launch of the pegylated interferons has had a dramatic effect on the market

for hepatitis treatments, with the improvements in side-effect profile and

efficacy leading to significant drug switching. Companies involved in this

sector need to reassess their competitive position and understand the new

dynamics of this sector.

Scope

In-depth profiles of all leading hepatitis B and hepatitis C products, including

recent event screens and key clinical trial data

Analysis of historical sales performance of all leading hepatitis products,

including quarterly seven major market sales from 1999 to 2003

Country specific forecasts for all leading products up to 2014 and in-depth

analysis of key events that will impact sales

Detailed analysis of life-cycle management and revenue protection strategies

available to key players

Highlights

The hepatitis market is expected to exhibit rapid growth to 2010, with a CAGR

greater than other infectious disease sectors (CAGR 2000-2010 = 9.0%). In the

short-term, Datamonitor expects continued uptake of existing products to drive

such growth, through geographical expansion and increased targeting of niche

populations.

The current lack of clinical differentiation between Pegasys and Peg-Intron

highlights the importance of effective life-cycle management strategies. During

the next 5 years, securing additional indications and geographical expansion

will prove more influential in determining hepatitis C market success than

efficacy and safety profiles.

The clear limitations of current hepatitis B (HBV) antiviral have led to

increased research assessing the potential of HBV combination therapy.

Datamonitor believes that the development of this concept will lead to increased

investment in antiviral R & D, alongside greater licensing and partnership

activity.

http://biz./bw/040728/285381_1.html

[Guest guest]

(never forget the business side of the meds.... Alley)

Research and Markets: Commercial Insight: Hepatitis B and C - Awaiting New

Developments

Wednesday July 28, 10:00 am ET

News and Analysis of Upcoming Hepatitis B and C Antivirals

DUBLIN, Ireland--(BUSINESS WIRE)--July 28, 2004-- Research and Markets

(http://www.researchandmarkets.com) has announced the addition of Commercial

Insight: Hepatitis B and C - Awaiting New Developments to their offering.

Introduction

The launch of the pegylated interferons has had a dramatic effect on the market

for hepatitis treatments, with the improvements in side-effect profile and

efficacy leading to significant drug switching. Companies involved in this

sector need to reassess their competitive position and understand the new

dynamics of this sector.

Scope

In-depth profiles of all leading hepatitis B and hepatitis C products, including

recent event screens and key clinical trial data

Analysis of historical sales performance of all leading hepatitis products,

including quarterly seven major market sales from 1999 to 2003

Country specific forecasts for all leading products up to 2014 and in-depth

analysis of key events that will impact sales

Detailed analysis of life-cycle management and revenue protection strategies

available to key players

Highlights

The hepatitis market is expected to exhibit rapid growth to 2010, with a CAGR

greater than other infectious disease sectors (CAGR 2000-2010 = 9.0%). In the

short-term, Datamonitor expects continued uptake of existing products to drive

such growth, through geographical expansion and increased targeting of niche

populations.

The current lack of clinical differentiation between Pegasys and Peg-Intron

highlights the importance of effective life-cycle management strategies. During

the next 5 years, securing additional indications and geographical expansion

will prove more influential in determining hepatitis C market success than

efficacy and safety profiles.

The clear limitations of current hepatitis B (HBV) antiviral have led to

increased research assessing the potential of HBV combination therapy.

Datamonitor believes that the development of this concept will lead to increased

investment in antiviral R & D, alongside greater licensing and partnership

activity.

http://biz./bw/040728/285381_1.html